Amgen to Present Long-Term Outcomes for Lumakras (Sotorasib) In KRAS G12C-Mutated NSCLC at Aacr 2022
Late-Breaking Oral Presentation Includes Two-Year Follow-Up Data from CodeBreaK 100 Study – the Most Advanced KRAS G12C Clinical Dataset
Pre-Clinical Data Evaluating Half-Life Extended BiTE® Molecule AMG 794 Targeting CLDN6 to be Presented for the First Time
Amgen announced that new data from across its oncology portfolio and pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans, Louisiana.
Long-term outcomes from the CodeBreaK 100 trial of LUMAKRAS® (sotorasib), the first and only KRASG12C inhibitor approved for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), will be shared as a late-breaking oral presentation on Sunday, April 10, 2022 from 3:00 – 5:00 p.m. CST.
Recommended AI News: ParcelShield Launches’ SmartView
Notable data from Amgen’s oncology pipeline includes the first disclosure of preclinical results from AMG 794, a half-life extended (HLE) bispecific T-cell engager (BiTE®) molecule targeting Claudin 6 (CLDN6) in NSCLC and epithelial ovarian cancer, and TNB-928b, a T-cell engaging bispecific antibody utilizing a bivalent tumor-selective folate receptor alpha binding arm for the treatment of ovarian cancer.
“Following the approval of LUMAKRAS for KRAS G12C-mutated non-small cell lung cancer in nearly 40 countries around the world, we look forward to sharing the longest follow-up data ever presented with a KRASG12C inhibitor at this year’s AACR conference, further demonstrating the clinical benefit this transformative therapy can bring to patients,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “Across our oncology pipeline, we also look forward to sharing emerging early research highlighting how Amgen is advancing the next frontier of innovation in the treatment of cancers.”
Recommended AI News: MaxLinear Partners with MACOM and II-VI to Showcase 100Gbps Per Lane Multi-Mode Links at OFC
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.